The development and clinical use of biomarkers has dramatically changed the framework of Alzheimer's disease (AD) management, allowing the diagnosis at the mild cognitive impairment (MCI) stage. In 2015 we compared the prevalence and prognosis of AD at the MCI stage according to different criteria available at that time, and we found that the National Institute of Aging-Alzheimer Association (NIA-AA) criteria provided higher predictive accuracy for AD dementia after 3 years. Since then, we adopted these criteria in clinical practice.
Objective
To evaluate the long-term predictive accuracy of the ‘MCI due to AD - high likelihood’ criteria by taking advantage from an extended follow-up in a memory clinic setting.
Methods
Patients were diagnosed according to the ‘MCI due to AD - high likelihood’ criteria and followed up until conversion to dementia.
Results
One hundred and fourteen patients with ‘MCI due to AD - high likelihood’ were enrolled in the study and followed-up for 3.0 ± 1.8 [0.4–8.3] years. During the follow-up 106 (93.0%) patients progressed to dementia, 2 (1.8%) had stroke, 6 (5.3%) died, and none remained in MCI or reverted to normal cognitive status. The average survival time remaining in MCI, analyzed with Kaplan-Meier curve, was 3.2 (95% CI 2.9–3.6) years. Using a multivariate Cox proportional hazards regression model, patients with higher Mini-Mental State Examination kept the MCI status longer.
Conclusions
The diagnostic criteria of NIA-AA ‘MCI due to AD - high likelihood’ have an excellent long-term predictive accuracy in a memory clinic setting.
BocchettaMGalluzziSKehoePG, et al.The use of biomarkers for the etiologic diagnosis of MCI in Europe: an EADC survey. Alzheimers Dement2015; 11: 195–206.
2.
DuboisBVillainNFrisoniGB, et al.Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. Lancet Neurol2021; 20: 484–496.
3.
BiegerABrumWSBorelliWV, et al.Influence of different diagnostic criteria on Alzheimer disease clinical research. Neurology2024; 103: e209753.
4.
DuboisBFeldmanHHJacovaC, et al.Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol2007; 6: 734–746.
5.
DuboisBFeldmanHHJacovaC, et al.Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol2014; 13: 614–629.
6.
AlbertMSDeKoskySTDicksonD, et al.The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the national institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement2011; 7: 270–279.
7.
VosSJBVerheyFFrölichL, et al.Prevalence and prognosis of Alzheimer’s disease at the mild cognitive impairment stage. Brain2015; 138: 1327–1338.
8.
MarocoJSilvaDRodriguesA, et al.Data mining methods in the prediction of Dementia: A real-data comparison of the accuracy, sensitivity and specificity of linear discriminant analysis, logistic regression, neural networks, support vector machines, classification trees and random forests. BMC Res Notes2011; 4: 299.
9.
PetersenRCSmithGEWaringSC, et al.Mild cognitive impairment: clinical characterization and outcome. Arch Neurol1999; 56: 303–308.
10.
WardATardiffSDyeC, et al.Rate of conversion from prodromal Alzheimer's disease to Alzheimer's dementia: a systematic review of the literature. Dement Geriatr Cogn Dis Extra2013; 3: 320–332.
11.
JakAJBondiMWDelano-WoodL, et al.Quantification of five neuropsychological approaches to defining mild cognitive impairment. Am J Geriatr Psychiatry2009; 17: 368–375.
12.
BlessedGTomlinsonBERothM. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry1968; 114: 797–811.
13.
GarciaC. Blessed dementia rating scale (BDRS). In: De MendonçaAGuerreiroM (eds) Escalas e Testes na Demência, 3rd edition. Lisboa: Grupo de Estudos de Envelhecimento Cerebral e Demência, 2008, pp.105–106.
14.
RibeiroFde MendonçaAGuerreiroM. Mild cognitive impairment: deficits in cognitive domains other than memory. Dementia Cogn Geriatr Dis2006; 21: 284–290.
15.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders DSM-IV-TR. 4th Edition, text revision. Washington, DC: APA, 2000.
16.
FolsteinMFFolsteinSMcHughPR. Mini-Mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatric Res1975; 12: 189–198.
17.
GuerreiroMSilvaAPBotelhoA, et al.Adaptação à população portuguesa da tradução do Mini Mental State Examination (MMSE). Rev Port Neurol1994; 1: 9–10.
18.
LeuzyAChiotisKHasselbalchSG, et al.Pittsburgh Compound B imaging and cerebrospinal fluid amyloid-beta in a multicentre European memory clinic study. Brain2016; 139: 2540–2553.
19.
TeunissenCETumaniHEngelborghsS, et al.Biobanking of CSF: international standardization to optimize biomarker development. Clin Biochem2014; 47: 288–292.
20.
OliveiraFPMMoreiraAPde MendonçaA, et al.Can 11C-PiB-PET relative delivery R1 or 11C-PiB-PET perfusion replace 18F-FDG-PET in the assessment of brain neurodegeneration?J Alzheimers Dis2018; 65: 89–97.
21.
GarciaC. Doença de Alzheimer, problemas do diagnóstico clínico. Tese de Doutoramento. Lisboa: Faculdade de Medicina de Lisboa, 1984.
22.
GuerreiroM. Contributo da Neuropsicologia para o Estudo das Demências. Dissertação de Doutoramento em Ciências Biomédicas, Faculdade de Medicina de Lisboa, Lisboa, 1998.
23.
WechslerD. Wechsler memory scale. San Antonio, TX: Psychological Corporation, 1945.
24.
van MaurikISVosSJBosI, et al.Alzheimer's disease neuroimaging initiative. Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. Lancet Neurol2019; 18: 1034–1044.
25.
BosIVosSJFrölichL, et al.The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. Neurobiol Aging2017; 56: 33–40.
26.
JansenWJJanssenOTijmsBM, et al.Prevalence estimates of amyloid abnormality across the Alzheimer disease clinical spectrum. JAMA Neurol2022; 79: 228–243.
27.
PestanaPCCardosoSGuerreiroM, et al.Frequency, sociodemographic, and neuropsychological features of patients with subjective cognitive decline diagnosed using different neuropsychological criteria. Alzheimers Res Ther2024; 16: 261.
28.
JackCRJrAndrewsJSBeachTG, et al.Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimers Dement2024; 20: 5143–5169.
29.
DuboisBVillainNSchneiderL, et al.Alzheimer disease as a clinical-biological construct-an international working group recommendation. JAMA Neurol2024; 81: 1304–1311.
30.
SalemmeSLombardoFLLacorteE, et al.The prognosis of mild cognitive impairment: a systematic review and meta-analysis. Alzheimers Dement (Amst)2025; 17: e70074.
31.
VermeulenRJAnderssonVBankenJ, et al.Limited generalizability and high risk of bias in multivariable models predicting conversion risk from mild cognitive impairment to dementia: a systematic review. Alzheimers Dement2025; 21: e70069.
32.
CardosoSSilvaDAlvesL, et al.The outcome of patients with amyloid-negative amnestic mild cognitive impairment. J Alzheimers Dis2022; 86: 629–640.
33.
ChételatGOssenkoppeleRVillemagneVL, et al.Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease. Brain2016; 139: 2528–2539.
VanderschaegheGSchaeverbekeJBruffaertsR, et al.Amnestic MCI patients’ experiences after disclosure of their amyloid PET result in a research context. Alzheimers Res Ther2017; 9: 92.
36.
McGrattanAMPakpahanESiervoM, et al.Risk of conversion from mild cognitive impairment to dementia in low- and middle-income countries: a systematic review and meta-analysis. Alzheimers Dement (N Y)2022; 8: e12267.
37.
SilvaDCardosoSGuerreiroM, et al.Neuropsychological contribution to predict conversion to dementia in patients with mild cognitive impairment due to Alzheimer's disease. J Alzheimers Dis2020; 74: 785–796.
38.
WangXZhouSYeN, et al.Predictive models of Alzheimer's disease dementia risk in older adults with mild cognitive impairment: a systematic review and critical appraisal. BMC Geriatr2024; 24: 531.
39.
PereiraTCardosoSGuerreiroM, et al.Targeting the uncertainty of predictions at patient-level using an ensemble of classifiers coupled with calibration methods, venn-ABERS, and conformal predictors: a case study in AD. J Biomed Inform2020; 101: 103350.
